Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years

Screening for Breast Cancer: An Update for the U.S. Preventive Services Task Force

(2013) Heidi D. Nelson   ANNALS OF INTERNAL MEDICINE

Qualitative Assessment of the Progesterone Receptor and HER2 Improves the Nottingham Prognostic Index Up to 5 Years After Breast Cancer Diagnosis

(2010) Vanya Van Belle et al.   JOURNAL OF CLINICAL ONCOLOGY

Overdiagnosis in Cancer

(2010) H. G. Welch et al.   JNCI-Journal of the National Cancer Institute

Prognostic value of nodal ratios in node-positive breast cancer: a compiled update

(2009) Vincent Vinh-Hung et al.   Future Oncology

Lymph Node Ratio as an Alternative to pN Staging in Node-Positive Breast Cancer

(2009) Vincent Vinh-Hung et al.   JOURNAL OF CLINICAL ONCOLOGY

Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

(2009) Massimo Federico et al.   JOURNAL OF CLINICAL ONCOLOGY

Receipt of adjuvant systemic therapy among patients with high-risk breast cancer detected by mammography screening

(2008) Lauro Bucchi et al.   BREAST CANCER RESEARCH AND TREATMENT

Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial

(2008) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY